Relationship Between Total Body Protein and Cross‐Sectional Skeletal Muscle Area in Liver Cirrhosis Is Influenced by Overhydration

Cameron I. Wells, John L. McCall, Lindsay D. Plank – 24 July 2018 – Sarcopenia as defined by reduced skeletal muscle area (SMA) on cross‐sectional abdominal imaging has been proposed as an objective measure of malnutrition, and it is associated with both wait‐list mortality and posttransplant complications in patients with cirrhosis. SMA, however, has never been validated against the gold standard measurement of total body protein (TBP) by in vivo neutron activation analysis (IVNAA).

The Reactive Oxygen Species–Mitophagy Signaling Pathway Regulates Liver Endothelial Cell Survival During Ischemia/Reperfusion Injury

Ricky H. Bhogal, Christopher J. Weston, Susanne Velduis, Henri G. D. Leuvenink, Gary M. Reynolds, Scott Davies, Luu Nyguet‐Thin, Mohammed Alfaifi, Emma L. Shepard, Yuri Boteon, Lorraine Wallace, Ye H. Oo, David H. Adams, Darius F. Mirza, Hynek Mergental, Gillian Muirhead, Barnaby T. F. Stephenson, Simon C. Afford – 24 July 2018 – Ischemia/reperfusion injury (IRI) is the main cause of complications following liver transplantation. Reactive oxygen species (ROS) were thought to be the main regulators of IRI.

Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease

Cristina Margini, Giuseppe Murgia, Guido Stirnimann, Andrea De Gottardi, Nasser Semmo, Stefania Casu, Jaime Bosch, Jean‐François Dufour, Annalisa Berzigotti – 24 July 2018 – Obesity and steatosis have been associated with liver disease progression in patients with compensated advanced chronic liver disease (cACLD) (liver stiffness measurement [LSM] ≥ 10 kPa). The controlled attenuation parameter (CAP) estimates steatosis during LSM by transient elastography. We aimed to evaluate whether CAP is associated with the development of clinically relevant events in cACLD.

Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy

Maximilian A. Ardelt, Thomas Fröhlich, Emanuele Martini, Martin Müller, Veronika Kanitz, Carina Atzberger, Petra Cantonati, Martina Meßner, Laura Posselt, Thorsten Lehr, Jan‐Georg Wojtyniak, Melanie Ulrich, Georg J. Arnold, Lars König, Dario Parazzoli, Stefan Zahler, Simon Rothenfußer, Doris Mayr, Alexander Gerbes, Giorgio Scita, Angelika M. Vollmar, Johanna Pachmayr – 23 July 2018 – Therapeutic options for patients with advanced‐stage hepatocellular carcinoma (HCC) are very limited.

Subscribe to